{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T21:57:19Z","timestamp":1775771839059,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T00:00:00Z","timestamp":1473120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10354-016-0502-x","type":"journal-article","created":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T07:09:21Z","timestamp":1473145761000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Diagnosis and treatment of Paget\u2019s disease of bone","Diagnose und Behandlung der Knochenerkrankung Morbus Paget"],"prefix":"10.1007","volume":"167","author":[{"given":"Christian","family":"Muschitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xaver","family":"Feichtinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Haschka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Kocijan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,6]]},"reference":[{"key":"502_CR1","first-page":"683","volume":"126","author":"JD Ringe","year":"1984","unstructured":"Ringe JD, Jend HH, Becker H. Epidemiologie der Osteitis deformans Paget. Munch Med Wschr. 1984;126:683\u20136.","journal-title":"Munch Med Wschr"},{"key":"502_CR2","first-page":"68","volume":"19","author":"P Mikosch","year":"2012","unstructured":"Mikosch P, Trifina E, Roschger P, Haller J, Klaushofer K. Klinik und Diagnose des Morbus Paget. J\u00a0Mineralstoffwechsel Muskuloskelet Erkrank. 2012;19:68\u201373.","journal-title":"J Mineralstoffwechsel Muskuloskelet Erkrank"},{"key":"502_CR3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1359\/jbmr.2001.16.8.1379","volume":"16","author":"KW Lyles","year":"2001","unstructured":"Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget\u2019s disease of bone. J\u00a0Bone Miner Res. 2001;16:1379\u201387.","journal-title":"J Bone Miner Res"},{"key":"502_CR4","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.","journal-title":"BMJ"},{"key":"502_CR5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2007-1907","volume":"93","author":"BA Swiglo","year":"2008","unstructured":"Swiglo BA, Murad MH, Sch\u00fcnemann HJ, Kunz R, Vigersky RA, Guyatt GH, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR6","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1210\/jc.2014-2910","volume":"99","author":"FR Singer","year":"2014","unstructured":"Singer FR, Bone HG, Hosking DJ, Lyles KW, Murad MH, Reid IR, et\u00a0al. Paget\u2018s disease of bone: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab. 2014;99:4408\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(08)61035-1","volume":"372","author":"SH Ralston","year":"2008","unstructured":"Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget\u2019s disease of bone. Lancet. 2008;372:155\u201363.","journal-title":"Lancet"},{"key":"502_CR8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1148\/radiographics.22.5.g02se281191","volume":"22","author":"SE Smith","year":"2002","unstructured":"Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH. From the archives of the AFIP. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics. 2002;22:1191\u2013216.","journal-title":"Radiographics"},{"key":"502_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-198704000-00012","author":"B Maldague","year":"1987","unstructured":"Maldague B, Malghem J. Dynamic radiologic patterns of Paget\u2019s disease of bone. Clin Orthop Relat Res. 1987;(217):126\u201351. doi: 10.1097\/00003086-198704000-00012 .","journal-title":"Clin Orthop Relat Res"},{"issue":"Suppl 4","key":"502_CR10","doi-asserted-by":"crossref","first-page":"L151","DOI":"10.1007\/s00330-003-1927-3","volume":"13","author":"C L\u00f3pez","year":"2003","unstructured":"L\u00f3pez C, Thomas DV, Davies AM. Neoplastic transformation and tumour-like lesions in Paget\u2019s disease of bone: a pictorial review. Eur Radiol. 2003;13(Suppl 4):L151\u201363.","journal-title":"Eur Radiol"},{"key":"502_CR11","first-page":"523","volume":"5","author":"PH Shirazi","year":"1974","unstructured":"Shirazi PH, Ryan WG, Fordham EW. Bone scanning in evaluation of Paget\u2019s disease of bone. CRC Crit Rev Clin Radiol Nucl Med. 1974;5:523\u201358.","journal-title":"CRC Crit Rev Clin Radiol Nucl Med"},{"key":"502_CR12","first-page":"417","volume":"5","author":"I Fogelman","year":"1980","unstructured":"Fogelman I, Carr D. A comparison of bone scanning and radiology in the assessment of patients with symptomatic Paget\u2019s disease. Eur J Nucl Med. 1980;5:417\u201321.","journal-title":"Eur J Nucl Med"},{"key":"502_CR13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bone.2003.03.001","volume":"33","author":"MEMW Eekhoff","year":"2003","unstructured":"Eekhoff MEMW, Zwinderman AH, Haverkort DMAD, Cremers SCLM, Hamdy NAT, Papapoulos SE. Determinants of induction and duration of remission of Paget\u2019s disease of bone after bisphosphonate (olpadronate) therapy. Bone. 2003;33:831\u20138.","journal-title":"Bone"},{"key":"502_CR14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/art.1780400312","volume":"40","author":"L Alvarez","year":"1997","unstructured":"Alvarez L, Peris P, Pons F, Gua\u00f1abens N, Herranz R, Monegal A, et\u00a0al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget\u2019s disease activity. Arthritis Rheum. 1997;40:461\u20138.","journal-title":"Arthritis Rheum"},{"key":"502_CR15","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","volume":"41","author":"A Blumsohn","year":"1995","unstructured":"Blumsohn A, Naylor KE, Assiri AM, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem. 1995;41:1592\u20138.","journal-title":"Clin Chem"},{"key":"502_CR16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/clinchem\/42.2.210","volume":"42","author":"W Withold","year":"1996","unstructured":"Withold W, Schulte U, Reinauer H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem. 1996;42:210\u20137.","journal-title":"Clin Chem"},{"key":"502_CR17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.5650100318","volume":"10","author":"L Alvarez","year":"1995","unstructured":"Alvarez L, Gua\u00f1abens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et\u00a0al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget\u2019s disease. J\u00a0Bone Miner Res. 1995;10:458\u201365.","journal-title":"J Bone Miner Res"},{"key":"502_CR18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et\u00a0al. Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2018s disease. N Engl J Med. 2005;353:898\u2013908.","journal-title":"N Engl J Med"},{"key":"502_CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235\u201342.","journal-title":"J Pharmacol Exp Ther"},{"key":"502_CR20","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799\u2013809.","journal-title":"N Engl J Med"},{"key":"502_CR21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","volume":"22","author":"D Hosking","year":"2007","unstructured":"Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142\u20138.","journal-title":"J Bone Miner Res"},{"key":"502_CR22","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","volume":"26","author":"IR Reid","year":"2011","unstructured":"Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011;26:2261\u201370.","journal-title":"J Bone Miner Res"},{"key":"502_CR23","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","volume":"13","author":"ES Siris","year":"1998","unstructured":"Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, et\u00a0al. Risedronate in the treatment of Paget\u2019s disease of bone: an open label, multicenter study. J\u00a0Bone Miner Res. 1998;13:1032\u20138.","journal-title":"J Bone Miner Res"},{"key":"502_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","volume":"22","author":"DJ Hosking","year":"1998","unstructured":"Hosking DJ, Eusebio RA, Chines AA. Paget\u2019s disease of bone: reduction of disease activity with oral risedronate. Bone. 1998;22:51\u20135.","journal-title":"Bone"},{"key":"502_CR26","first-page":"1906","volume":"83","author":"FR Singer","year":"1998","unstructured":"Singer FR, Clemens TL, Eusebio RA, Bekker Risedronate PJ. A highly effective oral agent in the treatment of patients with severe Paget\u2019s disease. J\u00a0Clin Endocrinol Metab. 1998;83:1906\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","volume":"35","author":"IR Reid","year":"2004","unstructured":"Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, et\u00a0al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone. Bone. 2004;35:224\u201330.","journal-title":"Bone"},{"key":"502_CR28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1259\/0007-1285-60-717-849","volume":"60","author":"GW Dodd","year":"1987","unstructured":"Dodd GW, Ibbertson HK, Fraser TR, Holdaway IM, Wattie D. Radiological assessment of Paget\u2019s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol. 1987;60:849\u201360.","journal-title":"Br J Radiol"},{"key":"502_CR29","first-page":"961","volume":"81","author":"E Siris","year":"1996","unstructured":"Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et\u00a0al. Comparative study of alendronate versus etidronate for the treatment of Paget\u2019s disease of bone. J\u00a0Clin Endocrinol Metab. 1996;81:961\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(79)91318-7","volume":"1","author":"WB Frijlink","year":"1979","unstructured":"Frijlink WB, Bijvoet OL, te Velde J, Heynen G. Treatment of Paget\u2019s disease with (3-amino-1-hydroxypropylidene)-1, 1\u2011bisphosphonate (A.P.D.). Lancet. 1979;1:799\u2013803.","journal-title":"Lancet"},{"key":"502_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-016-0150-6","author":"IR Reid","year":"2016","unstructured":"Reid IR, Sharma S, Kalluru R, Eagleton C. Treatment of Paget\u2019s disease of bone with denosumab: case report and literature review. Calcif Tissue Int. 2016; doi: 10.1007\/s00223-016-0150-6 .","journal-title":"Calcif Tissue Int"},{"key":"502_CR32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1210\/jc.2013-3762","volume":"99","author":"SA Polyzos","year":"2014","unstructured":"Polyzos SA, Singhellakis PN, Naot D, Adamidou F, Malandrinou FC, Anastasilakis AD, et\u00a0al. Denosumab treatment for juvenile Paget\u2019s disease: results from two adult patients with osteoprotegerin deficiency (\u201cBalkan\u201d mutation in the TNFRSF11B gene). J\u00a0Clin Endocrinol Metab. 2014;99:703\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR33","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","volume":"98","author":"C Grasemann","year":"2013","unstructured":"Grasemann C, Sch\u00fcndeln MM, H\u00f6vel M, Schweiger B, Bergmann C, Herrmann R, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget\u2019s disease. J Clin Endocrinol Metab. 2013;98:3121\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et\u00a0al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617\u201327.","journal-title":"Bone"},{"key":"502_CR35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/archinte.1995.00430160167017","volume":"155","author":"E Wallace","year":"1995","unstructured":"Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med. 1995;155:1813\u20135.","journal-title":"Arch Intern Med"},{"key":"502_CR36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbmr.5650081209","volume":"8","author":"S Patel","year":"1993","unstructured":"Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget\u2019s disease of bone. J\u00a0Bone Miner Res. 1993;8:1467\u201373.","journal-title":"J Bone Miner Res"},{"key":"502_CR37","first-page":"241","volume":"7","author":"M Sammaa el","year":"1986","unstructured":"el Sammaa M, Linthicum FH, House HP, House JW. Calcitonin as treatment for hearing loss in Paget\u2019s disease. Am J Otol. 1986;7:241\u20133.","journal-title":"Am J Otol"},{"key":"502_CR38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5435\/00124635-200211000-00005","volume":"10","author":"R Iorio","year":"2002","unstructured":"Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J\u00a0Am Acad Orthop Surg. 2002;10:409\u201316.","journal-title":"J Am Acad Orthop Surg"},{"key":"502_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-197610000-00018","author":"GA Finerman","year":"1976","unstructured":"Finerman GA, Gonick HC, Smith RK, Mayfield JM. Diphosphonate treatment of Paget\u2019s disease. Clin Orthop Relat Res. 1976;:115\u201324. doi: 10.1097\/00003086-197610000-00018 .","journal-title":"Clin Orthop Relat Res"},{"key":"502_CR40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2106\/00004623-197860060-00015","volume":"60","author":"MH Meyers","year":"1978","unstructured":"Meyers MH, Singer FR. Osteotomy for tibia vara in Paget\u2019s disease under cover of calcitonin. J\u00a0Bone Joint Surg Am. 1978;60:810\u20134.","journal-title":"J Bone Joint Surg Am"},{"key":"502_CR41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.29.4.448","volume":"29","author":"JR Chen","year":"1979","unstructured":"Chen JR, Rhee RS, Wallach S, Avramides A, Flores A. Neurologic disturbances in Paget disease of bone: response to calcitonin. Neurology. 1979;29:448\u201357.","journal-title":"Neurology"},{"key":"502_CR42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"Chawla S, Henshaw R, Seeger L, Choy E, Blay J\u2011Y, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901\u20138.","journal-title":"Lancet Oncol"},{"key":"502_CR43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","volume":"17","author":"TP Staa van","year":"2002","unstructured":"van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget\u2019s disease of bone in England and Wales. J\u00a0Bone Miner Res. 2002;17:465\u201371.","journal-title":"J Bone Miner Res"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0502-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-016-0502-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0502-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T16:57:45Z","timestamp":1749574665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-016-0502-x"}},"subtitle":["A\u00a0clinical practice guideline","Eine klinische Praxisstudie"],"short-title":[],"issued":{"date-parts":[[2016,9,6]]},"references-count":43,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s10354-016-0502-x","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,6]]}}}